人类呼吸道合胞病毒A（HRSV）蛋白-ACROBiosystems百普赛斯

HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified)

表达区间及表达系统（Source）

HRSV (A) Fusion glycoprotein F0, His Tag (RSF-V52H6) is expressed from human 293 cells (HEK293).

Predicted N-terminus: Gln 26

蛋白结构（Molecular Characterization）

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 55.2 kDa. The protein migrates as 47-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素（Endotoxin）

Less than 1.0 EU per μg by the LAL method.

纯度（Purity）

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储（Storage）

After reconstitution, this product is stable after storage at -70°C for 3 months.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

For long term storage, the product is stable for up to 3 years at -70°C from date of receipt;

For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt.

背景（Background）

人呼吸道合胞病毒（HRSV）是婴儿急性下呼吸道疾病最常见的病原体，可导致终身反复感染。RSV融合糖蛋白（RSV F）是人血清中RSV中和抗体的主要靶标。RSV F是一种I型病毒融合蛋白，合成为无活性的单链多肽，组装成三聚体。RSV F通过不可逆的蛋白质折叠将病毒和宿主细胞膜从不稳定的融合前构象融合到稳定的融合后构象。这两个州都表现出被中和抗体靶向的表位，融合后的RSV F正在被开发为候选疫苗。